NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Pliant Therapeutics, Inc. (PLRX) Stock Analysis

Pliant Therapeutics, Inc. (PLRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PLRX

$0.89

−$0.03 (−2.92%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PLRX with… →

PLRX Key Statistics

As of Oct 21, 2026
Trading
Open
$0.93
Previous Close
$0.91
Day's Range
0.88–0.93
52-Week Range
0.88–1.95
Volume
340.62K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.28
Valuation
Market Cap
$54.85M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.50
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$149.34M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
61.92M
1-Year Return
−52.63%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
417.79K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PLRX closed at $0.89, −52.63% over 1 year.

Pliant Therapeutics, Inc. (PLRX) has a market capitalization of $54.85M.

In fiscal 2025, PLRX reported revenue of $0.00.

PLRX Stock Return by Calendar Year

Pliant Therapeutics, Inc. (PLRX) return since Jun 2020: what $10,000 became

1 year
$10,000 $4,737
−52.63%
5 years
$10,000 $513
−94.87%
Since Jun 2020
$10,000 $416
−95.84%

If you had invested $10,000 in Pliant Therapeutics, Inc. (PLRX) at the close on June 3, 2020, the earliest close on record here, it would have been worth $416 at the close on October 21, 2026: −95.84% in total, −39.24% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−27.39%
2025−90.74%
2024−27.28%
2023−6.31%
2022+43.19%
2021−40.58%
2020 (partial year)+6.67%

As of October 21, 2026.

PLRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$149.34M—
2024$0.00−$210.30M—
2023$1.58M−$161.34M−10,211.1%
2022$9.69M−$123.32M−1,273.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$156.37M−$149.34M—
2024$0.00—−$228.37M−$210.30M—
2023$1.58M—−$184.15M−$161.34M−10,211.1%
2022$9.69M—−$127.20M−$123.32M−1,273.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Pliant Therapeutics, Inc. (PLRX) is capitalised at $54.85M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 49.

The 52-week range on file runs from $0.88 to $1.95. The most recent close on file for PLRX is $0.89, dated October 21, 2026. That is −$0.03 (−2.92%) against the previous close. The latest close sits 1.23% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $149.34M. Trailing earnings per share are −1.5.

Across the 4 fiscal years on file, revenue moves from $9.69M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 1.28. Daily returns over the trailing 6 years annualize to a volatility of 100.4%. The trailing one-year total return is −52.63%. Across 5 years the annualized return works out at −44.80%.

Growth & Income

The record shows no dividend for PLRX.

2026 is still running; the total return is −27.39% year to date. The strongest complete calendar year on file is 2022 at +43.19%; the weakest is 2025 at −90.74%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

Pliant Therapeutics, Inc. (PLRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Pliant Therapeutics, Inc. PLRX $54.85M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Pliant Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Visit website →